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ABSTRACT 
 
BACKGROUND Whilst our knowledge of white matter (WM) pathology underlying cognitive 
impairment in relapsing remitting multiple sclerosis (MS) is increasing, equivalent understanding in 
those with secondary progressive (SP) MS lags behind.  
 
OBJECTIVE To test the hypothesis that the extent and severity of WM tract damage differ between 
cognitively impaired (CI) and cognitively preserved (CP) SPMS patients. 
 
METHODS Conventional MRI and diffusion MRI were acquired from 30 SPMS patients and 32 healthy 
controls (HC). Cognitive domains commonly affected in MS patients were assessed. Linear regression 
was used to predict cognition. Diffusion measures were compared between groups using tract based 
spatial statistics. 
 
RESULTS Twelve patients were classified as CI, and processing speed was the most commonly 
affected domain. The final regression model including demographic variables and radial diffusivity 
explained the greatest variance of cognitive performance (R2=0.48, p=0.002). SPMS patients showed 
widespread loss of WM integrity throughout the WM skeleton when compared with HC. When 
compared with CP patients, CI patients showed more extensive and severe damage of several WM 
tracts, including the fornix, superior longitudinal fasciculus and forceps major. 
 
CONCLUSION Loss of WM integrity assessed using TBSS helps to explain cognitive decline in SPMS 
patients. 
 
   
 
 
INTRODUCTION 
 
Secondary progressive (SP) multiple sclerosis (MS) is associated with greater cognitive deficits than 
relapsing remitting MS (RRMS)(1). However, whilst our knowledge of WM pathology underlying 
cognitive impairment in RRMS is increasing, equivalent understanding in those with SPMS lags 
behind(2).           
 Diffusion tensor imaging (DTI) allows the assessment of WM integrity in vivo(3). Elements of 
cognitive decline in RRMS patients have been attributed to disconnection of regions involved in 
cognitive processing(4). Although, degeneration of chronically demyelinated axons is a prominent 
feature of progressive MS(5), other pathological processes could explain cognitive dysfunction in 
SPMS. For example, grey matter (GM) atrophy might play an important role since loss of GM is a 
well-known contributor to cognitive impairment and is more substantial in SPMS than RRMS(6). 
Recently, in SPMS patients more severe WM tract damage has been linked with cognitive impairment  
(7). However, given that pathology beyond WM integrity may influence cognitive outcomes, a more 
comprehensive approach is needed to examine the contribution of WM abnormalities to cognitive 
dysfunction in SPMS.  
Therefore, we investigated the influence of WM integrity, GM atrophy, WM lesions and 
demographic factors on cognitive performance in SPMS patients. Furthermore, we tested the 
hypothesis that the extent and severity of WM abnormalities differ between cognitively preserved 
and cognitively impaired patients, after accounting for demographic factors. 
 
   
 
 
MATERIAL AND METHODS 
 
Participants and clinical assessments  
SPMS patients(8) who were at least three months free from clinical relapses and attending the MS 
clinics at the National Hospital of Neurosurgery and Neurology were recruited. A group of healthy 
controls (HC), who did not suffer from any neurological or neuropsychiatric disorders and were not 
first-degree relatives of people with MS, also participated into this study. On the day of scanning, the 
MS participants underwent neurological assessment, including the Expanded Disability Status Scale 
(EDSS)(9) and the Multiple Sclerosis Functional Composite (MSFC) subtests(10).  
 The joint Medical Ethics Committee of the National Hospital for Neurology and Neurosurgery 
and the UCL Institute of Neurology, London approved the study. Written and informed consent was 
obtained from all participants. 
 
Cognitive assessments 
All subjects were invited to undergo cognitive assessment to examine five commonly affected 
cognitive functions in MS. Processing speed was assessed using the PASAT (3 seconds)(11) and 
Symbol Digit Modalities Test (SDMT)(12). Verbal memory was assessed using the immediate and 30-
minute delayed Story Recall Test (SRT) from the adult memory and information processing battery 
(AMIPB)(13) and the Recognition Memory Test (RMT) for words(14). Visual memory was measured 
using the immediate and 30-minute delayed complex Figure Recall Test (FRT) from the AMIPB and 
RMT for faces(14). Executive function was assessed using the Stroop colour-word interference 
test(15) and Hayling Sentence Completion Test(16). Working memory was assessed with the digit-
Span, a subtest of the Wechsler Adult Intelligence Scale-III(17). Premorbid IQ was assessed using the 
Wechsler Test of Adult Reading(18). Levels of anxiety and depression were measured using the 
Hospital Anxiety and Depression Scale (HADS)(19). For all cognitive domains, z-scores for each 
involved test were obtained with reference to the control participants and averaged. Patients were 
defined as cognitively impaired (CI) when their cognitive score was at least 2 standard deviations (SD) 
below that of controls on a minimum of 2 out of 5 tested cognitive domains. Additionally, an 
averaged cognition score was computed based on the five cognitive domains.    
      
 
 
 
 
   
 
 
Image acquisition and analysis 
MRI scanning was performed on a Philips Achieva 3T system (Philips Healthcare, Best, The 
Netherlands) using a 32-channel receive-only head-coil.  
 
T1-weighted scans and normalised brain volumes  
For brain volume measurements, all subjects underwent a three-dimensional inversion-prepared fast 
spoiled gradient recall (3D FSPGR) T1-weighted sequence (TR 13.3 ms, TE 4.2 ms, inversion time 450 
ms, 124 contiguous axial slices, slice thickness of 1.5 mm, FOV 300×225 mm, matrix size 256×160 
(reconstructed to 256×256 for a final in plane resolution of 1.17 mm)). NGMV was computed from 
segmented T1-weighted images using SIENAX software. 
 
T2-weighted scans and lesion probability mask  
For WM lesion detection, turbo spin-echo dual-echo proton density- and T2-weighted images were 
obtained (FOV 240x180 mm2, repetition time 3500 ms, echo time 19/85 and 50 axial slices, 1x1 x3 
mm3). Lesion marking was carried out by an experienced rater (VS) using JIM version 5. To assess 
whether diffusion differences were co-localized with focal lesions, a lesion probability map (LPM) was 
created(20).  
 
Diffusion MRI and TBSS  
All subjects underwent a whole-brain, cardiac gated, spin-echo diffusion-weighted sequence (TR = 
24000 ms; TE = 68 ms; 72 axial slices with an isotropic 2 mm resolution) with 61 volumes with non-
collinear diffusion gradients (b-value of 1200 s mm-2) and 7 volumes without diffusion weighting. 
After correction of motion and eddy current distortions using FMRIB's Linear Image Registration Tool, 
a diffusion tensor model was fitted on a voxel-by-voxel basis using DTIFIT from the FMRIB's Diffusion 
Toolbox (FSL, FMRIB Image Analysis Group, Oxford, UK). From the tensor fractional anisotropy (FA), 
axial diffusivity (AD), radial diffusivity (RD) and mean diffusivity (MD) images were derived. The 
default tract-based spatial statistics (TBSS) pipeline (version 5.2) was used to perform voxel-based 
diffusion tensor MRI analyses across subjects(21).  
Group comparisons of diffusion measures were conducted using a permutation algorithm 
(“randomise” from FSL) with 10,000 permutations using threshold-free cluster enhancement (TFCE) 
(p<0.05 family wise error (FWE) corrected). In particular, we performed the following group 
comparisons, each consisting of two contrasts: (I) cognitively preserved (CP) versus HC, (II) CI versus 
HC and (III) CI versus CP. All group comparisons for diffusion measures were conducted while treating 
age, gender and premorbid IQ as covariates.  
   
 
 
In addition to the whole brain analysis, we created regions of interest (ROIs) based on the 
John Hopkins University Atlas(22) which is commonly used as a ROI template for WM tracts(7). 
Additionally, ROI masks were created of the corpus callosum and fornix. To estimate the degree of 
damage in the patient groups, the following two analyses were performed:  1) the “extent” of 
damage was determined by calculating the percentage of significantly abnormal (p<0.05) voxels for 
the different diffusion metrics; and 2) the “severity” of damage was calculated per patient, by 
converting the diffusion measures to Z-scores, based on the mean and standard deviations of WM 
values in HC(23).  
 
Statistical analysis  
Statistical analyses were performed using SPSS software, version 21 (Chicago, Illinois, USA). Variables 
were checked for normality using Kolmogorov-Smirnov testing and histogram inspection. T2 lesion 
volumes were log-transformed. Chi-square tests were used to compare group differences for 
categorical variables.          
 Predicting averaged cognition employed linear regression analyses. Age, sex and premorbid 
IQ were first entered in block 1. To examine the additional explained variance of the MRI measures, 
NGMV, WM integrity and WM lesion load were entered one by one in block 2. Due to strong 
multicollinearity of the four diffusion measures, they could not be included as separate predictors in 
linear regression model. Therefore, the metric which showed the strongest correlation with 
cognition, was included as a measure of WM integrity.  
For group differences regarding diffusion measures, a one-way between group analysis of 
covariance (ANCOVA) including age, gender and premorbid IQ as covariates was conducted, using 
post-hoc Bonferroni comparisons to assess specific group differences. A more stringent alpha level 
was considered as significant (p<0.01) to correct for multiple comparisons. 
 
   
 
 
 
RESULTS 
 
Demographic characteristics  
30 patients with SPMS and 32 HC underwent MRI, and all patients and 23 HCs underwent cognitive 
assessment (Table I). Twelve patients were classified as cognitively impaired (CI), of which four 
patients showed impairments in two cognitive domains, five in three cognitive domains, two in four 
domains and one in five domains.  
 
[Insert table I here]  
 
Cognitive profile SPMS 
For all SPMS patients together, processing speed was most commonly impaired (15 patients, 50%), 
followed by executive function (10 patients, 33%). For CI patients, the group means of executive 
functioning and processing speed were respectively 4.1 and 2.9 SD below the mean of the HC (Table 
II).  
 
[Insert table II here]  
 
MRI characteristics 
CP and CI patients had both lower NGMV than HC (for each p<0.05), but no difference in NGMV was 
observed between patient groups (p=0.122) (Table III). Mean skeleton FA, RD and MD values were 
more abnormal in CI patients than in CP patients, who showed lower WM integrity when compared 
with HC (all tests had p<0.05). CP and CI patients did not differ with respect to WM lesion load 
(p=0.09) and mean skeleton AD (p=0.07) (Table III). Lesion load was not correlated with diffusion 
measures.  
 
[Insert table III here]  
 
Predictors of cognition 
Mean skeleton RD was selected as a measure of WM integrity, because it showed correlation with 
cognition (r=-0.359; p<0.05). The regression model with age, sex and premorbid IQ explained 42% of 
the variance of cognition in SPMS patients (F=6.32; p=0.002). This indicated that worse cognitive 
performance was associated with lower premorbid IQ (=0.672; p<0.001), female sex (=-0.274; 
p=0.09) and higher age (=-0.213; p=0.18). A regression model only containing premorbid IQ 
explained 30% of the total variance of cognition (F=11.93, p=0.002). Entering MRI measures to the 
   
 
 
regression model containing only demographic factors, led to a small increase in explained variance 
of 2% by including NGMV (R2=0.44; F=4.95; p=0.004), 4% by including lesion load (R2=0.46; F=5.42; 
p=0.003) and 6% by including mean skeleton RD (R2=0.48; F=5.78; p=0.002). The test statistics refer 
to the final regression model. A model containing demographic factors and MRI measures together 
explained 51% of the variance (F=3.97; p=0.007).  
 
TBSS findings: extent of WM damage 
The extent of whole-skeleton WM damage is summarised in figure I. Relative to CP patients, lower 
FA values were observed for 50% of the investigated WM, and higher RD, MD and AD values were 
seen for respectively 47%, 22% and 10% of the investigated WM in CI patients.   
 
[Insert figure 1 here]  
 
TBSS findings: extent of tract-specific WM damage 
CI and CP patients compared with HC 
When looking at the voxel-based differences in diffusion measures between groups, a widespread 
reduction in FA was observed throughout the skeleton in both patient groups when compared with 
HC. CP patients showed the greatest extent of FA reduction in the fornix, corpus callosum, right 
cingulate gyrus, forceps major and forceps minor when compared with HC (Figure 2A). Although 
largely overlapping results were observed for the other diffusion measures, the right inferior fronto-
occipital fasciculus was amongst the most extensively affected tracts when looking at RD, MD and 
AD. Additionally, the bilateral uncinate fasciculi showed an extensive increase in RD and MD relative 
to HC, whereas extensively increased AD was observed in the corticospinal tracts (Figure 2B-D).  
Similar WM tracts were affected in CI patients; however this patient group showed an 
additional loss of WM integrity of several tracts. When looking at the most extensively damaged WM 
tracts, the right inferior longitudinal fasciculus and right inferior fronto-occipital belonged to WM 
tracts with the highest percentage of decreased FA per tract volume (Figure 2E). Additionally, the 
right superior longitudinal fasciculus was amongst the most extensively affected tracts in CI patients 
relative to HC when looking at MD and AD (Figure 2F-G).  
These diffusion abnormalities overlapped with the distribution of WM lesions, but changes 
were also detected outside MS WM lesions (Figure 2). 
 
 
[Insert figure 2 here]  
 
   
 
 
CI patients compared with CP patients 
CI patients showed the most extensive FA reductions in the fornix, corpus callosum, bilateral 
uncinate fasciculi, left superior longitudinal fasciculus (temporal and frontal part) and left inferior 
fronto-occipital fasciculus compared with CP patients (with changes in more than 57% of tract voxels) 
(Figure 3A). Similar regions showed extensive differences for the other diffusion measures. The left 
corticospinal tract, however, demonstrated the greatest increases in RD and AD, in CI relative to CP 
patients (Figure 3B-D). 
 
[Insert figure 3 here]  
 
TBSS findings: severity of tract-specific WM damage 
CI patients showed, relative to CP patients, significant decreases in FA and increases in RD within the 
fornix, forceps major and left superior longitudinal fasciculus (p<0.01). Additionally, FA of the 
bilateral anterior thalamic radiation and inferior fronto-occipial fasciculi also differed between CP 
and CI patients (p<0.01) (Supplementary tables I-IV).   
 
 
   
 
 
DISCUSSION 
 
We found that demographic variables had the largest contribution in explaining cognition in SPMS. 
Whole-brain MRI measures generally explained little additional variance, although the final models 
remained significant. Of the whole brain MRI measures, when combined with the demographic 
variables, WM integrity (i.e. RD) appeared to be the strongest predictor, altogether accounting for 
48% of the variance in cognition in SPMS. CI patients demonstrated more extensive and severe 
microstructural changes in WM tracts when compared with CP patients.  
 
Cognitive dysfunction of SPMS patients 
Consistent with previously published studies using similar criteria(1), 40% of our SPMS patients was 
defined as cognitively impaired, with a predominant involvement of processing speed and executive 
function. Together with age, gender and premorbid IQ, WM integrity significantly explained 48% of 
the variance of cognitive performance in SPMS patients. Although, WM lesion volume and NGMV 
together with age, gender and premorbid IQ explained more variance than a model containing only 
these demographic factors, WM integrity (i.e. RD) explained the most additional variance. Although 
RD was more severely and extensively abnormal in CI than CP patients, mean skeleton RD added little 
to the regression model to predict cognitive impairment. A possible explanation could be that 
different measures of cognition were used as dependent variable for the regression model (e.g. 
averaged cognition) and TBSS analysis (e.g. CP and CI). A recent study reported that WM skeleton FA 
significantly predicted cognition in SPMS patients(7). However, the diffusion measures FA and RD are 
highly correlated, and reduced FA is probably driven by an increased RD.  Corresponding to a number 
of studies(24), higher premorbid IQ seems to influence the expression of cognitive deficits in SPMS. 
This could reflect the role of education and early life intellectual enrichment as major protective 
factor against cognitive impairment.  
 
WM tracts critical for cognitive function were more affected in CI patients  
TBSS enabled us to examine changes in WM integrity of the major WM tracts across the brain, 
independent of demographic factors. In doing so, we demonstrate that cognitive dysfunction in 
patients with SPMS is related to loss of WM integrity within a number of WM tracts, including the 
fornix, corpus callosum, bilateral uncinate fasciculi, left superior longitudinal fasciculus and left 
inferior fronto-occipital fasciculus. Many of these tracts have previously been linked to cognition in 
healthy participants, such as the uncinate fasciculus that connects parts of the limbic system with the 
orbitofrontal cortex and is involved in executive function(25) and the fornix, the major efferent 
pathway from the hippocampus, is known to be crucial for the formation of memories(26). 
   
 
 
Additionally, in CI patients more WM abnormalities were also observed in the cortical spinal tract 
which is not primarily involved in cognition. However, a number of studies have shown that cognitive 
impairment is linked to wider motor and sensory disturbances in MS (for example 27).   
 In addition, by visually examing figure 1 and 2 it seems that relative to HC, CI patients showed 
predominantly more extensive loss of WM integrity in tracts linking cortical structures one to the 
other than CP patients. This difference may play a significant and important role in the establishment 
of cognitive impairment and has previously been documented in a mixed sample of MS patients(28). 
However, CP patients also showed loss of WM integrity in regions known to be involved in cognitive 
processes, such as the fornix and uncinate fasciculi. Greater capacity for functional reorganization or 
the protective value of higher premorbid IQ are likely to play a role to maintain cognitive 
function(28,29).  
 
The structural correlates of cognitive dysfunction in SPMS patients 
Our observed changes in diffusion measures between CP and CI patients were unlikely to be 
primarily due to WM lesions, given no correlation was observed between lesion load and diffusion 
measures. This finding corresponds to previous DTI studies in which the involvement of NAWM in 
RRMS has been shown (28,30). Whether damage to axons traversing lesions or a more diffuse injury 
process underlies NAWM changes is uncertain. Nevertheless, recent evidence indicates that WM 
integrity is often reduced in NAWM near lesions(31) suggesting, that the role of lesions in cognitive 
dysfunction may be underestimated by considering only abnormalities in regions that are close to 
lesions, rather than broader, network-level effects of lesions. Diffusion changes were especially 
severe in FA and RD opposed to AD, thought to be indicative more of demyelination than axonal 
loss(32). However, this should be interpreted with caution, because the principal diffusivities are 
calculated in vivo in regions of low coherence of WM tracts(33). Therefore, it is likely that a 
combination of pathological changes is associated with the changes in diffusion measures. 
 
Limitations and conclusions 
A few limitations apply to this work. Larger patient groups are desirable in future studies when 
contrasting CI vs. CP SPMS patients. Using the currently observed differences in diffusion metrics 
between CI and CP patients, and the observed standard deviations, we calculated that a sample size 
of N=17 per group would be able to detect significant differences in diffusion metrics, with 80% 
power and an alpha level set at 0.05. Additionally, it is desirable to aim for even numbers of subjects 
when contrasting two groups. For the TBSS analysis it is not possible to test or correct for differences 
in variance between groups. Although we considered a more stringent alpha level as significant 
(p<0.01) for the group comparisons regarding diffusion measures conducted in SPSS, a formal 
   
 
 
correction for multiple comparisons was not made. However, we reported 13 significant results 
associated with a p-value less than 0.01, whilst one would expect on average 1 out of 100 false 
positive results, so it is unlikely that a type I error accounts for all these significant results.  Since we 
used the SIENAX tool to estimate the volume of brain tissues, it may have underestimated changes in 
deep GM (34). Given these regions are linked to cognitive processes(35), it is possible that better 
estimation of changes in these regions would have affected our results.  
In conclusion, as with RRMS(4,30), damage to WM tracts also appears to be a potential mechanism 
for cognitive impairment in SPMS patients. The present study shows that loss of WM integrity 
assessed using TBSS helps to explain cognitive decline, and emphasizes the relevance of studying 
patterns of WM disruption throughout the brain in relation to cognitive deficits. 
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